Policy/Access

Contemplating how the pandemic may change the regulatory landscape?

RESOURCES

Assessing and managing issues around clinical trials: a multi-stakeholder approach

Many companies are facing challenging decisions on whether to proceed with clinical trials in the coming months as countries experience varying degrees of lockdown.

View

COVID-19 has caused enforced digitalization of clinical practice – but how much will stick?

We have seen a digital revolution sweep across clinical practice, driven by the extraordinary circumstances of the coronavirus.

View

Telehealth comes to the forefront

Telehealth, in particular, has been waiting for its moment. In the U.S., the first recorded instance of telemedicine happened more than 60 years ago (!) when the Nebraska Psychiatry Institute began using closed-circuit TV for psychiatric consultations.

View

Unlocking virtual medical congresses

Medical congresses – crucial for the presentation of trial data, scientific exchange and the opportunity to engage with medical professionals, patient advocates, media and analysts – have been cancelled, postponed or are moving to virtual/part virtual.

View

No two virtual congresses are the same

Each congress has a different structure to its overall program and method in delivering its scientific information, despite stating that they all plan to keep to the traditional congress format.

Download PDF

Get in Touch

We know there are numerous considerations when it comes to the impact of COVID-19 on clinical trials and what this means for your organization. We are here to help.